These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 798193)

  • 21. Effect of gemfibrozil in vitro on fat-mobilizing lipolysis in human adipose tissue.
    Carlson LA
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):101-3. PubMed ID: 1019147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CI-719 in hyperlipoproteinaemia: interim data.
    Bremner WF; Third JL; Clark B; Corstorphine C; Lawrie TD
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):83-7. PubMed ID: 798201
    [No Abstract]   [Full Text] [Related]  

  • 23. Extrinsic factors affecting the response to gemfibrozil.
    Huunan-Seppälä A; Manninen V; Burton R; Eisalo A
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):53-7. PubMed ID: 1019154
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of gemfibrozil on plasma lipoprotein-apolipoprotein distribution and platelet reactivity in patients with hypertriglyceridemia.
    Sirtori CR; Franceschini G; Gianfranceschi G; Sirtori M; Montanari G; Tremoli E; Maderna P; Colli S; Zoppi F
    J Lab Clin Med; 1987 Sep; 110(3):279-86. PubMed ID: 3475394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The evaluation of lipoprotein changes during gemfibrozil treatment.
    Janus ED; Costa D; Ononogbu IC; Lewis B
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):76-7. PubMed ID: 1019156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gemfibrozil--a new lipid lowering agent.
    Nash DT
    J Med; 1980; 11(2-3):107-16. PubMed ID: 6931871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gemfibrozil for hyperlipidemia.
    Med Lett Drugs Ther; 1982 Jun; 24(612):59-60. PubMed ID: 6953310
    [No Abstract]   [Full Text] [Related]  

  • 28. The effect of CI-719 on lipolysis in rat adipose tissue.
    Elkeles RS; Ashwell M; Priest R; Durrant M
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):98-100. PubMed ID: 1019159
    [No Abstract]   [Full Text] [Related]  

  • 29. The metabolism of gemfibrozil.
    Okerholm RA; Keeley FJ; Peterson FE; Glazko AJ
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):11-4. PubMed ID: 828261
    [No Abstract]   [Full Text] [Related]  

  • 30. Gemfibrozil in a group of diabetics.
    de Salcedo I; Gorringe AL; Silva JL; Santos JA
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):64-70. PubMed ID: 1019155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Lipid therapy in risk patients. Do we concentrate too much on LDL cholesterol?].
    März W
    MMW Fortschr Med; 2005 Apr; 147(14):14. PubMed ID: 15887675
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparison of the metabolism and pharmacokinetics of metbufen and itanoxone and their analogues in rats.
    Chanal JL; Audran M; Bret MC; Cousse H; Fauran F; Rieu JP
    Arzneimittelforschung; 1988 Oct; 38(10):1454-60. PubMed ID: 3196384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. I. Changes in lipid levels after treatment (the "net" reduction)].
    Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Jamska B; Nowacki G
    Przegl Lek; 1987; 44(12):828-36. PubMed ID: 3330252
    [No Abstract]   [Full Text] [Related]  

  • 34. The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate.
    Nye ER; Sutherland WH; Temple Wa
    N Z Med J; 1980 Nov; 92(671):345-9. PubMed ID: 6935550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gemfibrozil therapy in patients with coronary heart disease.
    Bell H; Dittmeier G; Martinez L
    Mo Med; 1988 Jan; 85(1):27-30. PubMed ID: 3277032
    [No Abstract]   [Full Text] [Related]  

  • 36. Potential hypolipidemic agents. XI. Synthesis, plasma lipid-lowering properties and bioavailability of some esters of 2-(4-dibenzofuranoloxy)-2-methylpropionic acid.
    Bondesson G; Högberg T; Magnusson O; Stjernström NE
    Acta Pharm Suec; 1975; 12(4):361-74. PubMed ID: 1199735
    [No Abstract]   [Full Text] [Related]  

  • 37. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. II. Relation between the results of treatment and type of dyslipoproteinemia].
    Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Iwanejko J; Nowacki G
    Przegl Lek; 1987; 44(12):837-43. PubMed ID: 3330253
    [No Abstract]   [Full Text] [Related]  

  • 38. Lipid lowering effects on cardiovascular morbidity and mortality. Clinical evidence and therapeutic guidelines.
    Islami Y; Ribeiro LG
    Arq Bras Cardiol; 1988 Jul; 51(1):43-8. PubMed ID: 3073735
    [No Abstract]   [Full Text] [Related]  

  • 39. New lipid-lowering drug now on the market.
    JAMA; 1982 Mar; 247(11):1540. PubMed ID: 6950126
    [No Abstract]   [Full Text] [Related]  

  • 40. Synthesis and antihyperlipaemic activity of some novel N-cyanovinylformamidines.
    Shishoo CJ; Chhabria MT; Gandhi TP; Bangaru RA
    Arzneimittelforschung; 1997 Jan; 47(1):35-8. PubMed ID: 9037441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.